Neuroendocrine Cancers (M Cives, Section Editor)

New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms

Emilia Fortunati[1],[*] iD
Giulia Argalia[1]
Lucia Zanoni[2]
Stefano Fanti[1],[2]
Valentina Ambrosini[1],[2]

Address
[*],[1]Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
Email: emilia.fortunati@studio.unibo.it
[2]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy

This article is part of the Topical Collection on *Neuroendocrine Cancers*

Opinion statement

Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumours derived from cells of neuroendocrine origin and can potentially arise everywhere in the human body. The diagnostic assessment of NEN can be performed using a variety of PET radiopharmaceuticals. Well-differentiated NEN (NET) present a high expression of SSTR (somatostatin receptors) and can therefore be studied with 68Ga-DOTA-peptides ([68Ga]Ga-DOTANOC, [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE). Current guidelines recommend the use of SSTR imaging to assess disease extension at staging/restaging, follow-up, assessment of response to therapy and selection of patients who may benefit from radionuclide therapy (PRRT). [18F]F-FDG is used for the assessment of high-grade tumours (high-grade G2, G3 and NEC) and in every case, there is one or more mismatched lesions between diagnostic CT (positive) and SSTR-PET/CT (negative). [18F]F-DOPA is currently used for the assessment of medullary thyroid carcinoma, neuroblastoma, primary pheochromocytoma and abdominal paraganglioma. In recent years, however, several new tracers were designed exploiting the many potential targets of the neuroendocrine cell and were employed in clinical trials for both imaging and therapy. Currently, the real-life clinical impact of these tracers is still mostly not known; however, the favourable biodistribution (e.g. [68Ga]Ga-FAPI, SSTR antagonists) and the possibility to use new theranostic pairs may provide novel

diagnostic as well as therapeutic options (e.g. [68Ga]Ga-PSMA, [64Cu]Cu-SARTATE, [68Ga]Ga-CXCR4) for NEN patients.

Introduction

NEN are a rare and heterogeneous group of tumours, for both primary tumour site and clinical behaviour over time. In fact, their clinical presentation varies from relatively indolent tumours (most frequently) to more aggressive forms showing rapid progression. The most common primary site is represented by the gastro-entero-pancreatic (GEP) tract (mostly pancreas and ileum) and the lungs [1•]. Most NEN are well differentiated (NET, neuroendocrine tumours) and express somatostatin receptors (SSTR) that represent the cellular target for currently approved radiopharmaceuticals used for both diagnosis and therapy. NET are further subdivided into three pathological grades: G1 (Ki-67 <2%), G2 (Ki-67 3-20%) and G3 (Ki-67 >20%), showing a more favourable behaviour as compared to poorly differentiated neuroendocrine carcinomas (NECs, small and large cells) [2•]. Lung tumours are still classified as typical and atypical forms [3].

Nuclear medicine plays a crucial role in the routine diagnostic and therapeutic (radionuclide therapy, PRRT) flow chart of NEN. On the diagnostic side, most NET are accurately studied with [68Ga]Ga-DOTA-peptides while the forms with variable-to-low SSTR expression can be detected by [18F]F-DOPA (neuroblastoma, medullary thyroid carcinoma, pheochromocytoma, abdominal paraganglioma) [4]. [18F]F-FDG is generally used in undifferentiated forms (NECs), in high-grade NET G2 and NET G3, to detect more aggressive clones that generally drive the patients' prognosis. Moreover, [18F]F-FDG can be used to characterise lesions that do not show substantial [68Ga]Ga-DOTA-peptides uptake and, when mis-matched, represent a contraindication to PRRT. On the therapeutic side, [90Y]Y-DOTATOC and [177Lu]Lu-DOTATATE have been extensively used for target treatment of SSTR-positive NET and [177Lu]Lu-DOTATATE has been approved by European Medicines Agency (EMA) [5] and Food and Drug Administration (FDA) for routine treatment. PRRT efficacy was demonstrated in many different studies with limited toxicity and tremendous impact on the patients' quality of life. Current guidelines recommend the use of [18F]F-DOPA [4] as first choice tracer for the assessment of medullary thyroid carcinoma, neuroblastoma, pheochromocytoma and abdominal paraganglioma.

The NET cell, however, offers several different targets that can be exploited to design novel radiopharmaceuticals for both imaging and therapy. In recent years, several new compounds were investigated in clinical trials with particular interest towards new potentially theranostic pairs that could be employed for both imaging and target therapy. The purpose of this review is to summarise the current indications of clinically employed radiopharmaceuticals (68Ga-DOTA-conjugated peptides and their theragnostic pairs) as well as to discuss the preliminary results of the use of new emerging (Table 1) for NEN.

68Ga-DOTA-conjugated peptides

Diagnostic performance and theragnostic use

The first functional imaging diagnostic method to study NET was scintigraphy with radiolabelled SSTR analogues. Although this procedure represented a major breakthrough in the diagnostic flow-chart at first, it has been mostly replaced by novel beta-emitting radiopharmaceuticals targeting SSTR, when available. In fact, scintigraphy presents several limitations mostly due to a less favourable radiopharmaceutical biodistribution (especially at liver and bowel level) and lower spatial resolution (detection rate ranges between 50 and 100% [6]). The radiotracers for SSTR-PET/CT ([68Ga]Ga-DOTA-conjugated peptides)

Table 1. Emerging radiopharmaceuticals and their targets

Radiotracer	Targets	Advantages	Theranostic
SSTR agonists			
[18F]F-AlF-NOTA-octreotide	SSTR expression	- NET - High TBR	No
[18F]F-SiFAlin-TATE	SSTR expression	- NET - Favourable tumour-to-liver and tumour-to-spleen ratios	No
[64Cu]Cu-SARTATE	SSTR expression	- High tumour-to-liver ratio - Possibility of diagnostic studies and for prospective dosimetry for [67Cu]Cu-PRRT	Yes, [67Cu]Cu-SARTATE
SSTR antagonists (NODAGA-JR11; DOTA-JR11)	SSTR expression	- Compared to analogues: recognise a higher number of SSTR-binding sites, lower dissociation rate, higher TBR, not internalised	Yes, [177Lu]Lu-DOTA-JR11
Exendin	GLP-1R expression	- Insulinoma - High tumour-to-pancreas ratio	Yes, with the limit of high kidney uptake
[18F]F-MFBG	Norepinephrine transporter expression	- Neuroblastoma or paraganglioma/pheochromocytoma - High TBR	No
[68Ga]Ga-CXCR4	C-X-C motif chemokine receptor 4 expression	- Dedifferentiated NEN	Yes
[68Ga]Ga-PSMA	PSMA expression	- Highly vascularised lesions	Yes
[68Ga]Ga-FAPI	Fibroblast activation protein expression	- Preliminary data show uptake in NEN - Favourable biodistribution	Yes

Legend: *SSTR*, somatostatin receptor; *TBR*, tumour-to-background ratio; *GLP-1R*, glucagon-like peptide-1 receptor; *PSMA*, a transmembrane protein with enzymatic function as folate hydrolase-carboxypeptidase

imaging are represented by [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE and [68Ga]Ga-DOTANOC [6] and represent the current gold-standard for imaging SSTR-expressing NEN. The superiority of SSTR PET/CT over both scintigraphy and conventional diagnostic procedure has been extensively reported, especially for the detection of small lesions, nodal and bone metastasis. A recently published umbrella review collected the results of 34 meta-analyses [7], analysing the use diagnostic performance of different radiopharmaceutical (SSTR PET/CT, DOPA PET/CT, FDG PET/CT) in NENs or suspected NET as well as the impact on clinical management. SSTR PET/CT showed a very high sensitivity and specificity in well-differentiated SSTR-expressing NET (>90%) and impacted clinical management in approximately 40% of cases. Although these radiopharmaceuticals present differences in the SSTR-binding affinity,

they are considered clinically equivalent. Current guidelines [4, 8] recommend performing [68Ga]Ga-DOTA-conjugated peptides PET/CT for staging, re-staging after therapy and assessment of prognosis. Moreover, [68Ga]Ga-DOTA-conjugated peptides PET/CT is fundamental to demonstrate SSTR expression in vivo to select patients who might benefit from PRRT. Both DOTATOC and DOTATATE were used as theranostic compounds in clinical trials since the mid-nineties; however, [177Lu]Lu-DOTATATE was only recently approved. Moreover, although [177Lu]Lu-DOTATATE was originally approved for well-differentiated metastatic G1/G2 SSTR-positive mid-gut NET (NETTER-1 study) [9, 10], EMA/FDA extended its use also in pancreatic NET. The first multicentre, randomised phase 3 trial (NETTER-1) reported that progression-free survival (PFS) in the treated arm ([177Lu]Lu-DOTATATE PRRT + 30mg octreotide) was markedly longer than in the control-arm (FDA-approved off-label high-dose octreotide, 60mg) [9, 10]. PRRT should be considered a relatively safe treatment option. Among acute and short-term toxicity, nausea, vomiting and fatigue are common while patients report abdominal pain, diarrhoea and reversible mild haematologic toxicity less frequently. Alopecia and carcinoid crises are rare. Kidney and bone marrow are considered organs at risk for long-term PRRT toxicity: haematological reserve and renal function should be assessed before starting PRRT [11]. The phase III NETTER-1 study demonstrates that [177Lu]Lu-DOTATATE provides a substantial and clinically robust quality-of-life benefit for patients with progressive midgut NETs compared with high-dose octreotide [12••].

Emerging issues

Although [177Lu]Lu-DOTATATE PRRT is currently used in routine clinical practice, many issues are still debated including patients' selection criteria, the need of personalised treatment schemes, assessment of response to therapy, possibility of retreatment and when to use it in the therapeutic flow chart with respect to other treatment options. It is well known that PRRT achieves better results in patients presenting G1 and G2 tumours, due to their typically high SSTR expression. However, PRRT efficacy was also studied in patients with Ki-67>20%. Thang et al retrospectively evaluated 28 patients (Ki-67 ≤ 55%=22, Ki-67 > 55%=6; 17 had pancreatic, 5 small bowel, 3 large bowel, 2 bronchial and 1 unknown primary disease) treated with PRRT. Most patients showed FDG-positivity (25/28), received radiosensitising chemotherapy (20/28) and were treated for disease progression (89%). PRRT achieved a clinically relevant disease control with acceptable toxicity [13••], especially in patients with Ki-67 ≤ 55% in which PRRT might be considered as a first-line therapeutic option superior to platinum-based chemotherapy (provided the disease expresses high SSTR receptors with no discordant FDG-avid disease) [13••].

In a recent paper including 69 patients with NET G3 (primary sites: 46 pancreas, 11 unknown primary cancer, 6 midgut, 3 stomach, 3 rectum) treated with PRRT, PFS was significantly higher (11 vs 4 months) in patients with Ki-67 lower or equal to 55% (n = 53) as compared to G3 with higher Ki-67 levels. Moreover, 48 patients were also studied with baseline [18F]F-FDG-PET/CT: patients showing lesions with high [18F]F-FDG avidity (higher than the liver) presented shorter median PFS (7.1 months) and median OS (17.2 months) as compared to patients with lower [18F]F-FDG uptake (median PFS: 24.3 months

and median OS: 41.6 months). In the setting of G3 cases, this study shows that [18F]F-FDG was useful to identify patients with high uptake on SSTR-PET/CT and absent or faint [18F]F-FDG avidity, which were associated with a better long-term prognosis [14••]. The on-going NETTER-2 clinical trial aims in fact to assess the efficacy of [177Lu]Lu-DOTATATE PRRT as first-line treatment in patients with G2 and G3 GEP-NET compared to treatment with high dose (60 mg) long-acting octreotide [15••].

Another issue of debate regards [18F]FDG-PET/CT: it is currently not part of the standard pre-PRRT administration protocol, and the combined use of SSTR-PET/CT and [18F]FDG-PET/CT was proposed to better select patients who might benefit more from target therapy and to exclude from treatment those who present spatially mis-matched [18F]F-FDG/SSTR lesions. In view of the clinically relevant data provided by [18F]FDG-PET/CT, Chan et al developed the "NETPET score" that stratifies patients on the basis of the relative SSTR/[18F]F-FDG uptake: this score was proved to be prognostic and helpful to select PRRT candidates [16•].

Treatment scheme personalisation is another area of debate. The NETTER-1 trial promoted the standard use of a fixed-dose scheme for [177Lu]Lu-DOTATATE PRRT administration (7.4GBq x 4) in clinical practice. However, Sansovini et al reported (in 63 patients with histologically confirmed unresectable or metastatic G1-G2 pancreatic NET) that the use of customised activity (especially in selected patients at risk of developing serious adverse sequelae) had limited side effects and resulted in good tumour control [17]. Moreover, significantly longer PFS and OS were observed in patients in whom the 23 Gy dose limit to the kidney was reached [18]. Moreover, only limited data are currently available regarding PRRT retreatment (consisting in the administration of additional PRRT-courses in relapsing patients after response to the first PRRT course). In a cohort of 133 patients with gastrointestinal (GI, 62%), pancreatic (23%) and bronchopulmonary (BP, 11%) NEN treated with the first course of PRRT, PFS was respectively 30, 19 and 12 months. The G1 and G2 tumours had PFS of 25 and 22 months, compared to 11 months in G3-NEN. A minority of patients were offered subsequent PRRT treatment (36 patients had a second PRRT course while 8 patients received even a third course). After a second PRRT course, patients with G1 and G2 tumours showed a PFS of 19 and 22 months, respectively. The G3 tumours (only three patients re-treated) had a PFS of 4 months. This study demonstrated a favourable response also after a second course of PRRT, with a progression-free survival of 19 months across all primary tumours. The decision to retreat patients with a 2nd or even a 3rd course was mainly based on combination of the duration of response, toxicity and degree of uptake on SSTR-PET/CT. Patients who developed progression within 12 months were excluded from retreatment [19••]. In a recent meta-analysis, 13 studies described that PRRT retreatment was associated with an acceptable safety profile and promising efficacy: in patients with progressive GEP-NET who received retreatment with [177Lu]Lu-DOTATATE, median PFS was ≥ 12 months from the time of re-treatment [20].

In order to improve PRRT efficacy, the administration of the tracer directly into the hepatic artery [21] was suggested. In particular, patients with hepatic dominant metastases would benefit from this approach due to an increase of uptake of the radiopharmaceutical [22]. Furthermore, [177Lu]Lu-DOTATATE PRRT was also proposed in the neoadjuvant setting to reduce tumour size,

eventually rendering patients candidates for surgery [23•]. In the rare setting of paragangliomas, preliminary results demonstrate the superiority of [177Lu]Lu-DOTATATE PRRT compared to [131I]I-MIBG treatment [24]; however, the use in this clinical setting is still investigational.

[18F]F-AlF-NOTA-octreotide

Although 68Ga labelling offers the advantage of eluting the isotopes from a commercially available generator, therefore bypassing the need of an on-site cyclotron, on the other hand, the possibility to use fluorine labelling offers the advantage of a longer half-life, a better spatial resolution and a higher production yield with consistent benefits in imaging and logistical field. Recently, a novel SSTR agonist labelled with fluorine was synthesised: [18F]F-AlF-NOTA-octreotide, produced with the Al18F-method, with the advantages of a chelator-based radiolabelling method and the advantages of fluorine-18 in imaging and logistical field [25]. Preliminary data in 22 patients with proven NEN (16 GEP NEN: 2G1, 7G2, 7G3; 2 paragangliomas, 1 lung, 1 head/neck, 2 unknown primary carcinoma) compared [18F]F-AlF-NOTA-octreotide-PET/CT with [18F]F-FDG-PET/CT performed within 2 weeks. After 90 min, the radiotracer's localisation augmented in kidneys and bladder, while the spleen demonstrated the highest uptake. Physiological uptake was also detected at pituitary, thyroid, adrenal glands, uncinate process of the pancreas, stomach and intestine level. Brain, lung, muscle and bone showed a low background activity and spleen got the highest dose, as the urinary bladder. Images showed optimal contrast, with a significantly high tumour-to-background ratio. The brain uptake of [18F]F-AlF-NOTA-octreotide was low thanks to the intact blood-brain barrier, an important aspect for brain metastasis detection. The [18F]F-AlF-NOTA-octreotide tumour uptake was significantly higher than [18F]F-FDG uptake, depending on the differentiation grade: [18F]F-AlF-NOTA-octreotide SUVmax was higher in well-differentiated NET than in poorly differentiated tumours. Few tumours showed a "flip-flop" phenomenon, with variable affinity for both radiotracers at different sites: higher Ki-67 values were observed in [18F]F-FDG-avid lesions, while lower values were detected in [18F]F-AlF-NOTA-octreotide avid tumours [26••]. In a limited sample of six healthy volunteers and six NEN patients, [18F]F-AlF-NOTA-octreotide-PET/CT was compared to [68Ga]-Ga-DOTA-TATE-PET/CT performed within 6 months. The physiological uptake pattern was similar for both tracers, with lower uptake in most organs and bones for [18F]F-AlF-NOTA-octreotide and higher uptake in salivary glands for [68Ga]Ga-DOTATATE. [18F]F-AlF-NOTA-octreotide tumour uptake was lower in tumour lesions but increasing over the time, as demonstrated by all lesions' mean SUVmax progressive increase. Another important finding is the lower liver background uptake for [18F]F-AlF-NOTA-octreotide, which allowed it to identify more liver lesions as compared to [68Ga]Ga-DOTA-TATE. On the contrary, notwithstading the slightly lower background activity in the bone, [18F]F-AlF-NOTA-octreotide missed more bone lesion than [68Ga]Ga-DOTA-TATE, in particular in patients with a high number of bone lesions. Overall, these preliminary data (favourable biodistribution, dosimetry and tumours targeting) indicate [18F]F-AlF-NOTA-octreotide as a promising tracer for NET imaging [27••]. A further retrospective analysis, including 128 patients with

proven or suspected NEN (27 G1, 48 G2, 43 G3/NEC), also confirmed the favourable biodistribution, higher uptake in well differentiated tumours (G1/G2 vs G3) and in tumour lesions as compared to benign lesions (i.e. fractures or inflammatory lesions). Some G3 showed [18F]F-AlF-NOTA-octreotide uptake and no uptake with [18F]F-FDG, highlighting the importance of double tracer imaging [28•].

[18F]F-SiFAlin-TATE

[18F]F-SiFAlin-TATE is a novel and promising somatostatin analogue radiotracer labelled with 18F, showing the abovementioned advantages of fluorine-labelling (longer half-life, a better spatial resolution and a higher production yield with consistent benefits in imaging and logistical field) and the availability of a kit for labelling. The first-in-human [18F]F-SiFAlin-TATE-PET/CT scan was reported in 2019 in a patient with metastatic NET with unknown primary, presenting liver metastasis with Ki-67 of 5% and treated with emi-hepatectomy. Previous [68Ga]Ga-DOTATATE-PET/CT showed uptake in cardiac and bone metastasis, and PRRT was planned. [18F]F-SiFAlin-TATE-PET/CT performed prior to PRRT was comparable to [68Ga]Ga-DOTATATE-PET/CT for cardiac and bone metastasis, as well as the quantitative SPECT/CT performed after the first PRRT cycle, supporting its future use as an alternative to [68Ga]Ga-DOTA-conjugate-peptides-PET/CT [29••]. In a retrospective study including 13 patients with NEN (ileum=5, pancreas=2, lung=2, duodenal=1, colon=1, stomach=1, unknown=1; G1: 7 and G2: 6) studied with both [68Ga]Ga-DOTA-TOC and [18F]F-SiFAlin-TATE-PET/CT, tracers' biodistribution, tumour uptake and image quality were studied. [18F]F-SiFAlin-TATE biodistribution was higher, though not significantly, in the liver, adrenal glands and spleen. Significantly higher uptake was described, instead, in kidneys. Tumour uptake was calculated by SUVmax and SUVmean measurement, both in [18F]F-SiFAlin-TATE-PET/CT and [68Ga]Ga-DOTA-TOC-PET/CT, in 109 lesions (32 were liver metastasis, 28 bone, 24 lymph node, 7 subcutaneous, 7 peritoneal, 4 pleural, 2 lung, 3 myocardial and 2 ovarian metastasis): with the exception of lung lesions, a significantly higher [18F]F-SiFAlin-TATE tumour uptake was described in almost all tumour lesions. In comparison to [68Ga]Ga-DOTATOC, the higher tumour uptake led to a favourable tumour-to-liver and tumour-to-spleen ratios. Despite the heterogeneous population including different primary lesions undergoing various treatments, these preliminary data support the potential utility of [18F]F-SiFAlin-TATE [30••].

[64Cu]Cu-SARTATE

64Cu is a longer life positron-emitting radioisotope with a half-life of 12.7h. It is important to evaluate a predictive dosimetry and patients adequacy for [67Cu]Cu-PRRT, which is a β-emitting radionuclide with positive qualities for its use in therapy. Further good qualities of 64Cu are the favourable positron energy and production by cyclotron. It is reported a first-time-in-humans trial of [64Cu]Cu-MeCOSar-Tyr3-octreotate ([64Cu]Cu-SARTATE) which enrolled 10 patients with proven G1 or G2 NEN and a previous documented positivity on [68Ga]Ga-DOTATATE-PET/CT. Images were acquired at 30 min, 1h, 4h and

24h after [64Cu]Cu-SARTATE administration. The aim of this trial was to evaluate the high late-retention in tumour and clearance from the liver, to suggest suitability for prospective dosimetry for [67Cu]Cu-SARTATE PRRT. In most patients, image quality at 1h after injection of [64Cu]Cu-SARTATE can be considered comparable to that of [68Ga]Ga-DOTATATE at the same time. It is worth noticing how the lesion-to-liver ratio increased progressively in [64Cu]Cu-SARTATE scans between 4 and 24 h. So, delayed imaging may allow better lesion detection and improve sensitivity at liver level (a frequent metastasis site of NEN). All these aspects make [64Cu]Cu-SARTATE a safe PET/CT radiotracer, with good qualities for diagnostic studies and for prospective dosimetry for [67Cu]Cu-PRRT [31••]. Considering the few clinical reports, it is also interesting to evaluate the preliminary results portrayed in preclinical results. Cullinane et al. described, in the exocrine pancreatic tumour setting, that [67Cu]Cu-SARTATE has similar efficacy compared to [177Lu]Lu-TATE, with a significantly shorter half life which produces a higher dose-rate and with an elevated effectiveness [32]. Dearling et al. evaluated the possibility to detect and treat minimal residual disease of neuroblastoma in nude mice, showing the potential use of the theranostic pair of [64/67Cu]Cu-SARTATE [33].

SSTR antagonists

SSTR antagonists rather than agonists have the potential to improve SSTR-PET/CT imaging because they recognise a higher number of SSTR-binding sites, are not internalised and have a lower dissociation rate. In a prospective phase I study, [68Ga]Ga-OPS202 (NODAGA-JR11), a SSTR2 antagonist for PET/CT imaging, was investigated. It presented a high receptor's affinity, an acceptable radiation dose to organs and a low background activity (especially in the liver and gastrointestinal tract) [34]. In the subsequent prospective phase II study, they compared [68Ga]Ga-OPS202 and [68Ga]Ga-DOTATOC in patients with GEP NET. The antagonist showed substantially higher TBRs (tumour-to-background) and sensitivity at liver level. For malignant lymph nodes, there were no substantial differences between the two radiotracers in the TBR, regardless of the reference tissue [35•]. Regarding bone metastasis, the antagonist showed lower detection rate. Interestingly, [68Ga]Ga-DOTA-JR11 showed lower uptake than [68Ga]Ga-DOTATATE in normal organs such as spleen, renal cortex, adrenal glands, pituitary glands, stomach wall, normal liver parenchyma, small intestine, pancreas and bone marrow [36]. The corresponding therapeutic radiotracer, [177Lu]Lu-OPS201 (DOTA-JR11), demonstrated higher tumour radiation doses per administered activity and similar or lower radiation doses to normal organs as compared to [177Lu]Lu-DOTATATE [37]. Yordanova et al. confirm the largely concordant uptake from [68Ga]Ga-DOTA-JR11-PET and post-[177Lu]Lu-DOTA-JR11-SPECT/CT, making [68Ga]Ga-DOTA-JR11 and [177Lu]Lu-DOTA-JR11 a suitable theranostic pair [38•]. [177Lu]Lu-DOTA-LM3 is another recently reported radiopharmaceutical used for treatment: the first-in-human study in patients with metastatic NET reported an excellent tumour response with a disease control rate of 85.1% (attributable to the high doses delivered to the metastases) and a low nephrotoxicity and haematotoxicity [39••].

Theoretically, the major advantage of the use of the antagonists could lie in the possibility to improve detection of tumours presenting with a lower SSTR expression and to improve the detection of metastasis at liver level, thanks to the lower background.

Exendin

Insulinoma is one of the most common types of functional pancreatic NET arising from pancreatic β-cells. Clinically, it is characterised by hyperinsulinemia associated with hypoglycaemia. Since surgery is the main-stay of the treatment of insulinoma, the localisation of the neoplastic mass is of primary importance. However, the detection of the tumour is often challenging because insulinomas are often small sized and multifocal, and conventional imaging (CT, MRI) often show low sensitivity [40]. Moreover, only a minority of insulinomas express SSTR and can be detected by DOTA-peptides tracers. On the contrary, emerging evidence supports the use of radiotracers binding Glucagon-like peptide-1 receptor (GLP-1R), a G-protein-coupled receptor expressed on pancreatic beta cells and overexpressed in insulinoma. The instability of native GLP-1 (because of its rapid degradation by the enzyme dipeptidyl peptidase IV) makes it unsuitable for radiolabeling; therefore, Exendin-4, an agonist with strong binding affinity for GLP-1R, was synthesised. Gallium-68 was used for labelling NOTA-MAL-Cys39-exendin-4 [40]: [68Ga]Ga-NOTA-MAL-Cys39-exendin-4 demonstrated high accuracy for insulinoma localisation, with a high tumour-to-pancreas ratio. Literature data indicated that [68Ga]Ga-NOTA-MAL-Cys39-exendin-4 detection rate may decrease in case of small lesions, in case of malignant insulinomas (in which SSTRs are expressed with high density, whereas GLP-1 receptor expression is decreased or absent) and for lesions in the distal pancreas tail, next to the left kidney (site of physiological radiotracer excretion) [41••]. Exendin-4-based tracers for therapeutic applications have also been developed but, due to high kidney uptake, renal toxicity is a serious concern that currently limits its clinical application [42]. Preliminary preclinical evidence suggests that renal toxicity may be reduced, employing a novel exendin-4-based PET radiotracer conjugated with polyethylene glycol (PEG) ([18F]FB(ePEG12)12-exendin-4), that showed high tumour uptake and rapid kidney clearance [43•].

[18F]F-MFBG

[18F]F-meta-fluorobenzylguanidine ([18F]F-MFBG) is a fluorinated analogue of [123I]I-MIBG, labelled with 18F (half life of 110 min), which is accumulated in cells through the same norepinephrine transporter uptake mechanism of [123I]I-MIBG. The latter is currently clinically employed for NEN imaging and its major clinical applications are represented by imaging neuroblastoma, for both staging and follow-up. In the diagnostic setting, [123I]I-MIBG has been largely replaced by [18F]F-DOPA, also considering that approximately 10% of neuroblastoma are [123I]I-MIBG-negative. [123I]I-MIBG imaging however has a crucial role for the selection of patients candidate to nuclear therapy with [131I]I-MIBG. Although clinically useful, [123I]I-MIBG presents several limitations, including a poor imaging resolution and low quantitative accuracy [44••,

45]. The scan acquisition is long (particularly unfavourable considering that most patients are children), because images are acquired 20–24h after injection of [123I]I-MIBG. Patients' preparation is complicated since many drugs interfere with uptake and retention of [123I]I-MIBG, as tricyclic antidepressants, sympathomimetics and antihypertensives (children can be hypertensive) and should be therefore withdrawn. Moreover, thyroid blockage is compulsory, with the aim of preventing thyroid uptake of free radioactive iodide from the [123I]I-MIBG [46]. To overcome such issues, [18F]F-MFBG could be a successful alternative. The first-in-human prospective study of [18F]F-MFBG-PET/CT imaging involved ten patients with proven neuroblastoma or paraganglioma/pheochromocytoma [44••]. Preliminary data showed that [18F]F-MFBG, biodistribution included substantial activity in the blood pool, liver, salivary glands (that decrease with time) and a principal excretion by urinary tract (clearance resulted faster than [123I]I-MIBG). [18F]F-MFBG was overall well tolerated, with a distribution similar to [123I]I-MIBG. [18F]F-MFBG-PET/CT demonstrated high tumour-to-background ratios with optimal detection of lesions in bones and in soft-tissues (without substantial uptake difference between 1–2h and 3–4h after injection). Despite modest uptake in the liver, lesions were detectable with relatively high contrast at 3–4h after [18F]F-MFBG injections. Five additional lesions were detected at 3–4h post-injections as compared to 1–2-h imaging at liver level. Imaging at 1–2h after injection demonstrated the highest tumour-to-background ratios (TBR) for bone lesions and soft-tissue and this would be the optimal time point for imaging, providing the better high-contrast images and good lesion detection [44••]. In a report of a single case in a patient with metastatic pheochromocytoma, [18F]F-MFBG-PET/CT imaging was acquired 60min after radiotracer injection and a clinical [123I]I-MIBG scan was performed 27h post-injection. [18F]F-MFBG-PET/CT confirmed an optimal tumour targeting with better image quality than [123I]I-MIBG scans. This patient had already performed a [68Ga]Ga-DOTATATE-PET/CT, as a part of work up before the radionuclide therapy. The lower uptake on adrenal glands shown by the [18F]F-MFBG-PET/CT, compared to [68Ga]Ga-DOTATATE-PET/CT, allowed the identification of primary lesions located in adrenal glands [47•].

[68Ga]Ga-CXCR4

According to the literature C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in more aggressive and dedifferentiated NEN. Usually in the setting of tumours that poorly express SSTR, [18F]F-FDG is the PET tracer of choice. Weich et al. described the usefulness of CXCR4-directed imaging with the novel PET tracer [68Ga]Ga-Pentixafor as an alternative to [18F]FDG in poorly differentiated NEC; 11 patients were enrolled (the primary tumour, when identified, was located in the stomach, pancreas, oesophagus, ileum and rectum). [68Ga]Ga-Pentixafor positivity is associated with adverse prognosis, early progression and shortened overall survival [48••]. In fact, CXCR4 can be considered as a "tumour driver" which regulates the microenvironment and the dissemination of metastasis. In fact, [68Ga]Ga-Pentixafor spleen uptake in solid tumour patients correlates with the suppression of antitumour immune responses. In the setting of NEN, high spleen uptake is correlated with an

elevated leukocyte count and thrombocytosis possibly attributed to high tumour metabolism [49]. CXCR4 can also be labelled with the cytotoxic beta-emitters such 177Lu or 90Y generating the novel theranostic agent Pentixather for CXCR4-directed endoradiotherapy [50•], which has already been used, with varying degrees of success, in multiple myeloma and other haemato-oncological diseases [51]. Since this therapy leads to bone marrow ablation, further studies are needed to evaluate its utility in NET.

[68Ga]Ga-PSMA

Immunohistochemistry shows that prostate-specific membrane antigen (PSMA), notwithstanding its name, can be also overexpressed on the endothelial cells of the neo-vasculature of several types of solid tumours as well-differentiated thyroid carcinoma, lung adenocarcinoma, gastric/colon adenocarcinoma and renal carcinoma. Consequently, since [68Ga]Ga-PSMA first clinical use in prostate cancer patients, there is emerging evidence of its potential capacity to accidentally identify non-prostatic tumours [52]. Few reports indicate that [68Ga]Ga-PSMA can detect NET, typically characterised by [53•]. Two clinical cases of high [68Ga]Ga-PSMA focal uptake in the pancreas in patients with previous prostate cancer are known, which were later confirmed to be synchronous NET. Therefore, when evaluating a patient with prostate cancer, the incidental detection of PSMA-avid lesions of synchronous NET is possible [53•, 54•]. PSMA expression was also reported in two cases of medullary thyroid carcinoma (MTC) [55, 56], a condition generally challenging to treat: the use of [177Lu]Lu-DOTATATE-PRRT is only feasible in MTC presenting high SSTR (which is not common). Therefore, a potential, still unexplored treatment option could be represented by [177Lu]Lu-PSMA-PRRT in MTC cases showing substantial [68Ga]Ga-PSMA uptake [57•]. In further two cases of paragangliomas, which are usually asymptomatic and rare, [68Ga]Ga-PSMA uptake was also reported: these preliminary observations could offer a new therapeutic option for inoperable paragangliomas [58, 59]. Finally, another case report of prostate adenocarcinoma described [68Ga]Ga-PSMA uptake in a lesion with a clinical suspicion of pheochromocytoma showing also intense uptake in [68Ga]Ga-DOTA-peptide-PET/CT [60]. These preliminary data on [68Ga]Ga-PSMA indicate that it is important to consider the possibility of [68Ga]Ga-PSMA uptake in tumour entities beyond prostate cancer, even NEN, especially in patients showing [68Ga]Ga-PSMA uptake at sites that are uncommon for prostate cancer spread [61].

[68Ga]Ga-FAPI

[68Ga]Ga-FAPI is an emerging and promising radiotracer for PET/CT imaging, showing excellent preliminary results in various tumour entities [62]. FAPI is a fibroblast activation protein (FAP) inhibitor overexpressed by fibroblasts and associated with cancer and poor prognosis. Different kinds of tumours express strongly FAP, especially epithelial carcinomas. Radiopharmaceuticals with FAP-targeting were recently studied and are radiolabelled FAP-specific inhibitors (FAPI). In particular, biodistribution of [68Ga]Ga-FAPI is very low as compared to other tracers, including [18F]F-FDG, improving the detection of lesions at

brain, liver, head and neck, peritoneum, mesentery, omentum and axial skeleton level. Among all the FAPI tracers, FAPI-04 showed improved FAP binding and pharmacokinetics [63–65]. A single-centre retrospective analysis [66••] studied [68Ga]Ga-FAPI-PET/CT in 55 patients with rare tumours: cancer of unknown primary (*n* = 10), head and neck cancer (*n* = 13), gastrointestinal and biliary-pancreatic cancer (*n* = 17), urinary tract cancer (*n* = 4), neuroendocrine cancer (*n* = 4, although grade and primary site were not specified) and others (*n* = 7). Scans were acquired 60 min after tracer administration and three different [68Ga]Ga-labelled FAP ligands were used: FAPI-04, FAPI-46 and FAPI-74. At semiquantitative evaluation, a quite high value of SUVmax was measured in NET lesions, compared to others. One of the four patients enrolled by Dendl et al presented neuroendocrine metastasised urothelial bladder tumour showing high uptake both at 10 min after [68Ga]Ga-FAPI injection and after 1 h. This demonstrated the ability of [68Ga]Ga-FAPI-PET/CT to provide early diagnostic images [66••]. Kratochwil et al enrolled 3 NET patients in a retrospective study and described, despite a weak desmoblastic reaction observed at the histological examination, an intermediate [68Ga]Ga-FAPI uptake [62]. Several case reports indicated substantial uptake of [68Ga]Ga-FAPI in NET of different origins. A case of G2 (Ki-67: 15–20%) NET of the pancreas with hepatic metastasis underwent [68Ga]Ga-FAPI-04-PET/CT after [18F]F-FDG-PET/CT. [68Ga]Ga-FAPI-04-PET/CT showed high uptake both at pancreas level and as well as in a [18F]FDG-negative liver metastasis (thanks to the usually low liver background FAPI uptake) [67•]. Another G2 pancreatic NET (Ki-67: 10%) was studied with three radiopharmaceuticals: [68Ga]Ga-FAPI-04-PET/CT, [18F]F-FDG-PET/CT and [68Ga]Ga-DOTATATE-PET/CT. Tumour to liver ratio in [68Ga]Ga-FAPI-04-PET/CT was higher compared to the other tracers although [68Ga]Ga-DOTATATE could better detect a higher number of small liver metastatic lesions [68•]. Finally, Ergül et al described that [68Ga]Ga-FAPI-04-PET/CT uptake could be higher than [18F]F-FDG-PET/CT in liver NEC (Ki-67: 80%), suggesting a potential use for [68Ga]Ga-FAPI-04-PET/CT in NEC cases with low uptake on [18F]F-FDG-PET/CT [69•]. In conclusion, although very preliminary, these data indicate that FAPI is a tracer with favourable biodistribution in NEN: further studies are needed to better ascertain whether it could provide additional value in the clinical management of NEN (including both diagnosis and therapy) with elevated content of activated fibroblasts [70].

Conclusions

In clinical practice, agonists of the SSTR are employed for both diagnosis and therapy (PRRT) of well-differentiated NEN. In high grade G2, G3 and NEC, [18F]F-FDG is currently employed. [18F]F-DOPA is preferred in particular types of NEN such as medullary thyroid cancer, pheochromocytoma and abdominal paraganglioma.

In recent years, emerging evidence supports the potentially promising role of new radiopharmaceuticals that exploit different targets on the NET cells. Preliminary reports are mostly encouraging, indicating a more favourable biodistribution (e.g. [68Ga]Ga-FAPI, SSTR-antagonists), accuracy in particular settings (e.g. Exendin superiority over SSTR-agonist in the setting of insulinoma; [18F]F-MFBG superiority over [123I]I-MIBG) or

potential theranostic use (e.g. [68Ga]Ga-PSMA, [64Cu]Cu-SARTATE, [68Ga]Ga-CXCR4). However, the real-life clinical impact of these new radiopharmaceuticals is still mostly not known as a consequence of the limited number and very heterogenous cohorts of studied patients (in terms of primary site, Ki-67 levels, on-going treatments juts to name a few). Further studies are needed to better ascertain the clinical settings in which these tracers will provide an added value and definitive clinical impact.

Declarations

Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of interest
SF reports personal fees from AAA, Bayer, GE, Janssen, Novartis, Sofie, Telix and Astellas and grants to institution from Amgen and Telix. VA reports personal fees from EANM, ESMIT, AAA and ESMO and participation in ENETS Advisory Board, EANM Oncology Theranostic Committee, ITANET Scientific Board and ESMO Faculty. LZ reports personal fees from Springer (book editor) and Messaggi International Publisher & Events (invited congress speaker — topic not related to the current manuscript) and support for attending meeting from Hellenic Society of Nuclear Medicine, GE and Radius. EF and GA declare no competing interests.

Open Access

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:
- •   Of importance
- ••   Of major importance

1.•   Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60. https://doi.org/10.1016/j.annonc.2020.03.304
Very recent guidelines about diagnosis, treatment and follow-up.

2.•   Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8. https://doi.org/10.1111/his.13975
This is the last update of WHO classification of digestive system's tumours.

3.   Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J

Thorac Oncol. 2015;10(9):1243–60. https://doi.org/10.1097/JTO.0000000000000630.

4. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA [published correction appears in Eur J Nucl Med Mol Imaging. 2017 Aug 30;]. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601. https://doi.org/10.1007/s00259-017-3728-y.

5. Lutathera. https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera. Accessed 31/10/2021.

6. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601. https://doi.org/10.1007/s00259-017-3728-y.

7. Treglia, G.; Sadeghi, R.; Giovinazzo, F.; Galiandro, F.; Annunziata, S.; Muoio, B.; Kroiss, A.S. PET with different Ra-diopharmaceuticals in neuroendocrine neoplasms: an umbrella review of published meta-analyses. Cancers 2021, 13, 5172, https://doi.org/10.3390/cancers13205172.], PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

8. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM, O'Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP, all other Antibes Consensus Conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212–44. https://doi.org/10.1159/000471879.

9. A study comparing treatment with 177Lu-DOTA0-Tyr3-octreotate to octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours (NETTER-1). https://clinicaltrials.gov/ct2/show/NCT01578239. Accessed 28/10/2021.

10. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, et al. NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.

11. Van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172(1):R1–8. https://doi.org/10.1530/EJE-14-0488.

12.•• Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E. NETTER-1 Study Group. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36(25):2578–84. https://doi.org/10.1200/JCO.2018.78.5865

Recent phase III of NETTER-1 study demonstrates the impact of [177Lu]Lu-dotatate about quality-of-life for patients with progressive midgut NETs.

13.•• Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis [published correction appears in Eur J Nucl Med Mol Imaging. 2017 Nov 20;:]. Eur J Nucl Med Mol Imaging. 2018;45(2):262-277. https://doi.org/10.1007/s00259-017-3821-2.

A retrospective analysis, which enrolled patients with G3 NEN, demonstrated that PRRT achieved clinically relevant disease control with acceptable toxicity.

14.•• Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med. 2019;60(3):377–85. https://doi.org/10.2967/jnumed.118.215848

A recent paper including 69 patients with NET G3 treated with PRRT evaluated the baseline [18F]F-FDG utility to stratifying G3 NEN patients.

15.•• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET. https://clinicaltrials.gov/ct2/show/NCT03972488. Accessed 23/10/2021.

The ongoing clinical trial NETTER-2 aims to prove the efficacy of [177Lu]Lu-dotatate PRRT as first-line treatment in patients with G2 and G3 GEP-NET.

16.• Chan DL, Ulaner GA, Pattison D, et al. Dual PET imaging in bronchial neuroendocrine neoplasms: the NETPET score as a prognostic biomarker. J Nucl Med. 2021;62(9):1278–84. https://doi.org/10.2967/jnumed.120.257659

NETPET score stratified patients to be prognostic and helpful to select PRRT candidates.

17. Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490–9. https://doi.org/10.1007/s00259-016-3533-z.

18. Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728–42. https://doi.org/10.1007/s00259-018-4209-7.

19.•• Zacho MD, Iversen P, Villadsen GE, et al. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study. Scand J Gastroenterol. 2021;56(3):289–97. https://doi.org/10.1080/00365521.2021.1872095

This study evaluated PFS after PRRT retreatment, in a cohort of 133 patients with G1, G2 and G3 NEN.

20. Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2021;93:102141. https://doi.org/10.1016/j.ctrv.2020.10214.

21. Telo S, Filice A, Versari A, Lamberti G, Campana D, Calabrò D, Fanti S, Ambrosini V. Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. Clin Transl Imaging. 2021;9:423–38. https://doi.org/10.1007/s40336-021-00443-y.

22. Memorial Sloan Kettering Cancer Center (2021) A pilot study investigating intrahepatic arterial and intravenous infusion of the radiolabeled somatostatin agonist 177Lu-DOTATATE in patients with liver-dominant metastatic gastroenteropancreatic (GEP), bronchial or unknown primary well differentiated neuroendocrine tumors [Internet]. Report no NCT04544098. https://clinicaltrials.gov/ct2/show/NCT04544098 Accessed 31/10/2021.

23.• Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20(12):3049. https://doi.org/10.3390/ijms20123049

In this review, it is reported how [177Lu]Lu-DOTATATE PRRT can be important in the neoadjuvant setting.

24. Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, Caplin M, Khoo B. Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017 Mar;115(4):425–34. https://doi.org/10.1002/jso.24553.

25. Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, van Cutsem E, Verslype C, van Laere K, Bormans G, Deroose CM. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging. 2019;46(11):2398–9. https://doi.org/10.1007/s00259-019-04425-1.

26.•• Long T, Yang N, Zhou M, et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44(6):452–8. https://doi.org/10.1097/RLU.0000000000002578

This study compared [18F]F-AlF-NOTA-octreotide to [18F]F-FDG imaging in NEN patients, highlighting the advantages of the first radiotracers and of the combinations of the two radiotracers mentioned.

27.•• Pauwels E, Cleeren F, Tshibangu T, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47(13):3033-3046. https://doi.org/10.1007/s00259-020-04918-4.

A prospective trial in which [18F]F-AlF-NOTA-octreotide in compared to [68Ga]Ga-DOTATATE in NEN patients for the first time.

28.• Hou J, Long T, Yang N, et al. Biodistribution of 18F-AlF-NOTA-octreotide in different organs and characterization of uptake in neuroendocrine neoplasms [published online ahead of print, 2021 Jul 6]. Mol Imaging Biol. 2021; https://doi.org/10.1007/s11307-021-01628-7.

A retrospective analysis with the aim of evaluating [18F]F-AlF-NOTA-octreotide biodistribution and in which is highlighted the importance of dual imaging with [18F]F-FDG to fully evaluate NEN.

29.•• Ilhan H, Todica A, Lindner S, et al. First-in-human 18F-SiFAlin-TATE PET/CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging. 2019;46(11):2400-2401. https://doi.org/10.1007/s00259-019-04448-8.

First-in-human [18F]F-SiFAlin-TATE-PET/CT scan performed in a patient with metastatic NET with unknown primary, and also compared to [68Ga]Ga-DOTA-peptide-PET/CT.

30.•• Ilhan H, Lindner S, Todica A, et al. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870-880. https://doi.org/10.1007/s00259-019-04501-6.

A first retrospective study, in which 13 NEN patients were involved, comparing [18F]F-SiFAlin-TATE to [68Ga]Ga-DOTA-TOC.

31.•• Hicks RJ, Jackson P, Kong G, et al. 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med. 2019; 60(6):777-785. https://doi.org/10.2967/jnumed.118.217745.

A first-in-human trial enrolled 10 patients with proven G1 or G2, with the aim of evaluating [64Cu]Cu-SARTATE suitability for diagnostic aspects and for prospective dosimetry for [67Cu]Cu-PRRT.

32. Cullinane C, Jeffery CM, Roselt PD, van Dam EM, Jackson S, Kuan K, Jackson P, Binns D, van Zuylekom J, Harris MJ, Hicks RJ, Donnelly PS.

Peptide receptor radionuclide therapy with [67]Cu-CuSarTATE is highly efficacious against a somatostatin-positive neuroendocrine tumor model. J Nucl Med. 2020;61(12):1800–5. https://doi.org/10.2967/jnumed.120.243543.

33. Dearling JLJ, van Dam EM, Harris MJ, Packard AB. Detection and therapy of neuroblastoma minimal residual disease using [[64/67]Cu]Cu-SARTATE in a preclinical model of hepatic metastases. EJNMMI Res. 2021;11(1):20. Published 2021 Feb 25. https://doi.org/10.1186/s13550-021-00763-0

34. Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, Wild D. Safety, biodistribution, and radiation dosimetry of 68Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study. J Nucl Med. 2018 Jun;59(6):909–14. https://doi.org/10.2967/jnumed.117.199737.

35.• Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D. Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59(6):915–21. https://doi.org/10.2967/jnumed.117.199760

A prospective phase II imaging study, comparing [68Ga]Ga-OPS202 and [68Ga]Ga-DOTATOC in patients with GEP NET and evaluating TBR and sensitivity.

36. Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, Jia R, Xu J, Huo L. Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020 Jun;61(6):897–903. https://doi.org/10.2967/jnumed.119.235093.

37. Bodei L, Weber WA. Somatostatin receptor imaging of neuroendocrine tumors: from agonists to antagonists. J Nucl Med. 2018 Jun;59(6):907–8. https://doi.org/10.2967/jnumed.117.205161.

38.• Yordanova A, Biersack HJ, Ahmadzadehfar H. Advances in molecular imaging and radionuclide therapy of neuroendocrine tumors. J Clin Med. 2020;9(11):3679. https://doi.org/10.3390/jcm9113679

In this review, it is reported the possibility to consider [68Ga]Ga-DOTA-JR11 and [177Lu]Lu-DOTA-JR11 a suitable theranostic pair

39.•• Baum RP, Zhang J, Schuchardt C, Mueller D, Maecke H. First-in-human study of novel SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy. J Nucl Med. 2021 Mar 5:jnumed.120.258889. https://doi.org/10.2967/jnumed.120.258889.

The first-in-human study to assess the safety, dosimetry and efficacy of [177Lu]Lu-DOTA-LM3 therapy in patients with metastatic NET.

40. Zhang P, Zhao Z, Zhang L, Wu W, Xu Y, Pan D, Wang F, Yang M. [68Ga]Ga-NOTA-MAL-Cys39-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma. Nucl Med Biol. 2019; 74-75:19-24. https://doi.org/10.1016/j.nucmedbio.2019.08.002

41.•• Michalski K, Laubner K, Stoykow C, Omrane MA, Maecke HR, Seufert J, Goetz C, Meyer PT, Ruf J. Detection of insulinomas using dual-time-point 68Ga-DOTA-Exendin 4 PET/CT. Clin Nucl Med. 2020;45(7):519–24. https://doi.org/10.1097/RLU.0000000000003093

The evaluation of [68Ga]Ga-NOTA-MAL-Cys39-exendin-4 detection rate.

42. Jansen TJP, van Lith SAM, Boss M, Brom M, Joosten L, Béhé M, Buitinga M, Gotthardt M. Exendin-4 analogs in insulinoma theranostics. J Labelled Comp Radiopharm. 2019;62(10):656–72. https://doi.org/10.1002/jlcr.3750.

43.• Murakami T, Fujimoto H, Hamamatsu K, Yamauchi Y, Kodama Y, Fujita N, Fujikura J, Shimizu Y, Nakamoto Y, Kimura H, Saji H, Inagaki N. Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT. Sci Rep. 2021;11(1):15014. https://doi.org/10.1038/s41598-021-94595-6

In this paper are described the preclinical and preliminary evidence about a novel exendin-4-based PET radiotracer conjugated with polyethylene glycol (PEG) ([18F]FB(ePEG12)12-exendin-4.

44.•• Pandit-Taskar N, Zanzonico P, Staton KD, et al. Biodistribution and dosimetry of ^{18}F-meta-fluorobenzylguanidine: a first-in-human PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59(1):147–53. https://doi.org/10.2967/jnumed.117.193169

This is the first-in-human prospective study of [18F]F-MFBG-PET/CT imaging in patients with proven neuroblastoma or paraganglioma/pheochromocytoma.

45. Samim A, Tytgat GAM, Bleeker G, et al. Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. 2021;11(4):270. Published 2021 Apr 4. https://doi.org/10.3390/jpm11040270.

46. Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, Manea I, Koziorowski J, Castellani R, Boubaker A, Lambert B, Pfluger T, Nadel H, Sharp S, Giammarile F. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45(11):2009–24. https://doi.org/10.1007/s00259-018-4070-8.

47.• Pauwels E, Celen S, Vandamme M, et al. Improved resolution and sensitivity of [^{18}F]MFBG PET compared with [^{123}I]MIBG SPECT in a patient with a norepinephrine transporter-expressing tumour. Eur J Nucl Med Mol Imaging. 2021;48(1):313-315. https://doi.org/10.1007/s00259-020-04830-x.

A case report that compared [18F]F-MFBG-PET/CT to

[68Ga]Ga-DOTATATE-PET/CT and to [123I]I-MIBG scan in a patient with metastatic pheochromocytoma.

48.•• Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M. CXCR4-directed PET/CT in patients with newly diagnosed neuroendocrine carcinomas. Diagnostics (Basel). 2021;11(4):605. https://doi.org/10.3390/diagnostics11040605

The first study in which is evaluated the performance of CXCR4-directed imaging with the novel PET tracer [68Ga]Ga-Pentixafor.

49. Lewis R, Habringer S, Kircher M, Hefter M, Peuker CA, Werner R, Ademaj-Kospiri V, Gäble A, Weber W, Wester HJ, Buck A, Herhaus P, Lapa C, Keller U. Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res. 2021;11(1):77. https://doi.org/10.1186/s13550-021-00822-6.

50.• Yordanova A, Biersack HJ, Ahmadzadehfar H. Advances in molecular imaging and radionuclide therapy of neuroendocrine tumors. J Clin Med. 2020;9(11):3679. https://doi.org/10.3390/jcm9113679

A recent review describing the possibility of labelling CXCR4 with 177Lu or 90Y to generate Pentixather, a theranostic agent.

51. Lapa C, Hänscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, Samnick S, Kotzerke J, Einsele H, Buck AK, Wester HJ, Grigoleit GU. Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med. 2019;60(1):60–4. https://doi.org/10.2967/jnumed.118.210997.

52. Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe PJ, Beels L, Maes A. PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: a systematic review. Int J Mol Sci. 2019;20(19):4886. Published 2019 Oct 2. https://doi.org/10.3390/ijms20194886.

53.• Morales MI, Erhard A, Lozano MD, Quincoces G, Richter JA, Rodríguez-Fraile M. Incidental diagnosis of neuroendocrine tumour with ^{68}Ga-PSMA PET/CT: report of clinical case. Diagnóstico incidental de tumor neuroendocrino con ^{68}Ga-PSMA PET/TC: a propósito de un caso. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020;39(2):102–3. https://doi.org/10.1016/j.remn.2019.08.005

A case report in which the possibility of finding incidentale synchronous NET in a patient with prostate cancer is highlighted.

54.• Luong TV, Iversen P, Bouchelouche K, Arveschoug AK. 68Ga-prostate-specific membrane antigen uptake in a pancreatic neuroendocrine tumor. Clin Nucl Med. 2020;45(5):379-382. https://doi.org/10.1097/RLU.0000000000002997.

Another recent case report in which the possibility of finding incidentale synchronous NET in a patient with prostate cancer is described.

55. Arora S, Damle NA, Parida GK, Singhal A, Nalli H, Dattagupta S, Bal C. Recurrent medullary thyroid carcinoma on 68Ga-prostate-specific membrane antigen PET/CT: exploring new theranostic avenues. Clin Nucl Med. 2018;43(5):359–60. https://doi.org/10.1097/RLU.0000000000002010.

56. Ciappuccini R, Edet-Sanson A, Saguet-Rysanek V, Gauthé M, Bardet S. Thyroid incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT revealing a medullary thyroid carcinoma. Clin Nucl Med. 2019;44(8):663–5. https://doi.org/10.1097/RLU.0000000000002559.

57.• Arora S, Prabhu M, Damle NA, et al. Prostate-specific membrane antigen imaging in recurrent medullary thyroid cancer: a new theranostic tracer in the offing? Indian J Nucl Med. 2018;33(3):261–3. https://doi.org/10.4103/ijnm.IJNM_10_18

A case report which described the importance of PSMA expression to consider the potential use of [177Lu]Lu-PSMA in neuroendocrine tumours with the lack of somatostatin receptor expression.

58. Parihar AS, Vadi SK, Mittal BR, Kumar R, Bal A, Singh SK. 68Ga-PSMA-HBED-CC-avid synchronous urinary bladder paraganglioma in a patient with metastatic prostate carcinoma. Clin Nucl Med. 2018;43(9):e329–30. https://doi.org/10.1097/RLU.0000000000002172.

59. Tripathy S, Tripathi M, Dattagupta S, Parida GK, Shamim SA. In vivo PSMA expression in head and neck paragangliomas on 68Ga PSMA 11 PET/CT. Clin Nucl Med. 2019;44(6):e398–400. https://doi.org/10.1097/RLU.0000000000002581.

60. Singh D, Kumar R, Mittal BR, Singh H, Bhattacharya A. 68Ga-labeled prostate-specific membrane antigen uptake in pheochromocytoma: an incidental finding in PET/CT scan. *Clin Nucl Med*. 2018;43(9):688–90. https://doi.org/10.1097/RLU.0000000000002181.

61. Tyagi S, Singh SK, Narain TA, Singh H, Kumar R, Vadi SK. Synchronous paraganglioma masquerading as 68Ga-PSMA PET/CT-avid metastasis in carcinoma prostate-how specific is 68Ga-PSMA PET/CT? Clin Nucl Med. 2019;44(6):e420–2. https://doi.org/10.1097/RLU.0000000000002589.

62. Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5. https://doi.org/10.2967/jnumed.119.227967.

63. Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820–32. https://doi.org/10.1007/s00259-020-04769-z.

64. Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, Wu X, Guo W, Fan C, Wu J, Huang W, Lin Q, Sun L, Wu H.

Usefulness of [^{68}Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [^{18}F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48(1):73–86. https://doi.org/10.1007/s00259-020-04940-6.

65.   Giesel FL, Kratochwil C, Schlittenhardt J, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of ^{68}Ga-FAPI and ^{18}F-FDG PET/CT in cancer patients [published online ahead of print, 2021 Jun 17]. Eur J Nucl Med Mol Imaging. 2021; https://doi.org/10.1007/s00259-021-05307-1

66.••   Dendl K, Finck R, Giesel FL, et al. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies [published online ahead of print, 2021 Aug 3]. Eur J Nucl Med Mol Imaging. 2021; https://doi.org/10.1007/s00259-021-05488-9.

A retrospective analysis, involving different tumoural entities, which showed how [68Ga]Ga-FAPI can be considered a powerful imaging radiotracer, especially in epithelial carcinoma, as NET.

67.•   Wang H, Du Z, Huang Q, et al. The superiority of [^{68}Ga]Ga-FAPI-04 over [^{18}F]-FDG in a case of neuro-endocrine tumour with hepatic metastasis. Eur J Nucl Med Mol Imaging. 2021;48(9):3005-3006. https://doi.org/10.1007/s00259-021-05247-w.

A recent case report which highlighted the importance of comparison between [68Ga]Ga-FAPI-04 and [18F]F-FDG in a well-differentiated NET.

68.•   Cheng Z, Zou S, Cheng S, Song S, Zhu X. Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET/CT in a patient with pancreatic neuroendocrine tumor. Clin Nucl Med. 2021;46(9):764-765. https://doi.org/10.1097/RLU.0000000000003763.

Another recent case report, with the [68GaGa]Ga-FAPI scans are compared to [68Ga]Ga-DOTATATE and [18F]F-FDG scans in a patient with NEN.

69.•   Ergül N, Yılmaz B, Cin M, Çermik TF. 68Ga-DOTA-FAPI-04 PET/CT in neuroendocrine carcinoma of the liver with elevated AFP level: comparison with 18F-FDG PET/CT [published online ahead of print, 2021 Jul 20]. Clin Nucl Med. 2021. https://doi.org/10.1097/RLU.0000000000003811.

A very recent case report suggesting the use of [68GaGa]Ga-FAPI PET/CT in NEC with low uptake of [18F]F-FDG.

70.   Kömek H, Gündoğan C, Can C. 68Ga-FAPI PET/CT versus 68Ga-DOTATATE PET/CT in the evaluation of a patient with neuroendocrine tumor. Clin Nucl Med. 2021;46(5):e290–2. https://doi.org/10.1097/RLU.0000000000003490.

Publisher's note